The app of Zhii Tong Finance reported that Shanghai Haixin Group (600851.SH) released its semi-annual report for 2024, during which the company achieved operating income of 0.406 billion yuan, a decrease of 34.98% compared to the same period last year. The net income attributable to shareholders of the listed company was 0.102 billion yuan, an increase of 0.10% compared to the same period last year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 99.4779 million yuan, a decrease of 4.73% compared to the same period last year. The basic earnings per share was 0.0843 yuan.

The decrease in revenue of 34.98% is mainly due to the inclusion of Haixin Pharmaceutical in the merger scope in the same period last year. This period no longer includes Haixin Pharmaceutical in the merger scope, resulting in a decrease in revenue of 80.27 million yuan; the bulk trade income of this period decreased by 77.18 million yuan.